An antimalarial drug developed in Portland has begun enrolling patients in its first in-human study. The investigational drug, invented at Portland State University and developed by PSU spinoff DesignMedix, is a modified form of chloroquine, an established antimalarial drug that kills the parasites once they have infected human red blood cells. Many strains of the parasites that cause the deadliest form of malaria have developed resistance to chloroquine, and the parasites can expel the drug before…
Follow this link:
PSU and its spinoff usher antimalarial drug to human trials
